



Project Description: Arcoplast Antimicrobial 2'x4' Ceiling Tile

ICS has completed several Arcoplast projects for Clay-Park Labs over the past few years. We began in 2002 by installing Arcoplast Wall Liners and an Arcoplast Ceiling Tile Ceiling in one process room. Our relationship quickly grew, and now we usually complete at least one Arcoplast project for Clay-Park Labs each summer and each winter during their plant shut-downs. It has turned into an ongoing upgrade of their walls and ceilings, starting in the more critical areas and working out into the rest of the plant.

Our installations at Clay-Park Labs initiated testing on the Arcoplast wall and ceiling panels for toxicity compliance with the City of New York Department of Buildings. The tests were exhausting and expensive but rewarding and educational in the end. Upon exposure to fire the Arcoplast cement core panels did not produce products of decomposition or combustibility that were more toxic than those given off by wood or paper when decomposing or burning under comparable conditions. Arcoplast cement core panels were found acceptable by the City of New York Department of Buildings Material & Equipment Acceptance (MEA) Division.

Clay-Park Labs develops, manufactures, and markets generic topical drugs – prescription, OTC, cosmetic, and private label. The company was formed in 1975 and is a subsidiary of Agis Group, which was acquired by Perrigo in November 2004.